Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
June 07, 2021 at 13:26 PM EDT
Biogen's biologics license application for aducanumab, its investigational Alzheimer's treatment, received FDA approval under the accelerated approval pathway.
